Lilly Bullish On Diabetes/Oncology Products; Analysts Skeptical
This article was originally published in The Pink Sheet Daily
Executive Summary
The Indianapolis-based big pharma touted the value of its late-stage pipeline at an analyst meeting on Oct. 3, particularly its diabetes and oncology franchises, even though they face tough competition and have encountered some setbacks.